For a deeper understanding of peptide science, therapeutic applications, and emerging research trends, explore our Research Library.
The scale of investment flowing into peptide manufacturing and discovery right now is unlike anything the industry has seen before. Eli Lilly alone has committed over $27 billion to U.S. domestic production — and the moves made just in the past few months tell the story of where the entire field is heading. To explore how peptides are being studied, developed, and applied across research settings, visit our
In December 2025, Lilly announced a $6 billion active pharmaceutical ingredient facility in Huntsville, Alabama, the third of four new U.S. manufacturing sites, specifically designed to produce small molecule synthetic and peptide medicines including orforglipron, its oral GLP-1 drug. Construction begins in 2026. Then in January 2026, a $3.5 billion injectable manufacturing facility in Pennsylvania’s Lehigh Valley was announced to produce retatrutide and next-generation obesity therapies. That facility will be operational by 2031. Compounds like retatrutide are part of a newer class of multi-receptor agonists — outlined in our Retatrutide Research Overview.
The driver is obvious: peptide demand is outpacing existing supply infrastructure. The global peptide therapeutics market was valued at approximately $140 billion in 2025 and is projected to reach $164 billion in 2026, with North America commanding the largest share. Every new oral GLP-1 approval, every Phase 3 readout, every new indication expands the volume of peptide APIs the industry needs to produce — and the current manufacturing base wasn’t built for this scale.
But manufacturing capacity is only half the story. On March 29, 2026, Lilly announced a $2.75 billion collaboration with Insilico Medicine, a Hong Kong-based AI drug discovery company, to accelerate the identification and development of novel therapeutics using AI. Lilly receives exclusive global rights to develop and commercialize compounds emerging from the partnership, with Insilico receiving a $115 million upfront payment and milestone-linked compensation. Separately, Lilly has committed $1 billion over five years alongside Nvidia to build out the AI computing infrastructure needed to tackle bottlenecks in drug discovery.
The implication for peptide research is direct. AI-driven discovery platforms are compressing timelines from years to months, identifying peptide candidates with receptor specificity that would have taken traditional screening approaches far longer to find. What once required massive combinatorial chemistry programs can now be modeled computationally before a single compound is synthesized.
Advances in microwave-assisted solid-phase peptide synthesis have already reduced reaction times from hours to minutes while pushing crude purity levels above 90% — lowering the cost of producing research-grade compounds at scale. Add AI-guided sequence design on top of that, and the discovery-to-synthesis pipeline is being fundamentally restructured.
For the broader research peptide ecosystem, the signal is clear. When companies are committing billions to build the manufacturing infrastructure for a drug class, and simultaneously investing billions more to accelerate discovery within it, the field isn’t speculative anymore. The infrastructure is being built for a reason.
These developments point to a broader shift across peptide research and manufacturing — additional context can be found within our Popular Research Topics.
2026 Peptide Industry Report: Top Verified Research Peptide Vendors — BioLongevity Labs, 2026